News

On May 20, 2024, the FDA announced the approval of 2 products as interchangeable biosimilars to aflibercept—the first products to receive such a designation from the FDA.

The phase 3 QUASAR Maintenance study met its primary endpoint of clinical remission and demonstrated statistically significant endoscopic remission rates in UC treatment.

Sehgal explains the safety and efficacy of GLP-1RAs in patients with IBD as well as the impact on inflammatory biomarkers.

A numerically slower decline in eGFR was reported in the finerenone cohort after hospitalization for heart failure when compared with placebo.

Damas explains key findings from her pilot study exploring intervals of a low-calorie plant-based diet as adjunctive therapy to medication in patients with ulcerative colitis.

Use of dupilumab reduced exacerbations and improved lung function in COPD patients with type 2 inflammation.

Rezaie describes recent trends in GLP-1RA prescription patterns from his population-based research presented at DDW, highlighting increases in off-label use.

Fortman reviews the state of the 2021 AHA/ACC guideline recommendations to pursue shared decision making and cost-efficient testing strategies.

More than half of patients recruited for this research showed improvements in wound healing, and a significant number had greater wound stability.

Kilgore reviews early cognitive decline tools include AD8 and MoCA, and how they should be utilized at the primary care level.

TNF-α levels in the sweat correlate with serum values in patients with IBD, suggesting the wearable's feasibility in non-invasive disease monitoring.

Bludorn reviews preventive measures and strategic collaboration to ensure high-risk patients for conditions like heat stroke are identified before an acute event occurs.

An AAPA 2024 session reflected on the joint AHA/ACC chest pain guidelines, particularly the adoption of high-density troponin level testing since 2021.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on the role of advocacy and patient voice in HBV management.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on the most pressing unmet needs in HBV for 2024.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on updates in the therapeutic pipeline.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on the need to improve HBV screening and vaccination.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on how advancing understanding of HBV DNA integration is influencing care in 2024.

In this segment of our 6-part discussion on updates and unmet needs within the management of hepatitis B virus focuses on advances in the pathophysiology of hepatitis b virus for 2024.

Damas explains what inspired her research about the impact of a low-calorie plant-based diet on clinical response to medication in patients with ulcerative colitis.

During AAPA 2024, a group of session presenters provide recommendations for the next year's agenda based on trends and development.

Microbiota differences between individuals with and without MAFLD were associated with dietary intake and clinical outcomes.

Peterson reviews the gastric and hormonal events linked to drugs like tirzepatide, before considering whether incretin therapies will help to finally embrace obesity as the medical condition it is.

Findings were presented at DDW and highlight the feasibility of breath analysis for microbiome metabolic characterization in the digestive system.

Zhang explains disparities in HCC care and the negative impact on long-term outcomes, also addressing potential considerations for vulnerable patient populations.

The MyGut digital health monitoring platform proves feasible and impactful during integration into inflammatory bowel disease care.

Results presented at DDW detail the association between ALT, Fibroscan CAP, Fibroscan VCTE, and histological response to resmetirom in patients enrolled in MAESTRO-NASH.

Higher exposure dupilumab significantly improved histologic and endoscopic outcomes in children with EoE aged 1 to <12 years.